Adrenal hemorrhage and non-ST elevation myocardial infarction: an antiphospholipid syndrome dilemma

Reumatismo. 2023 Sep 18;75(3). doi: 10.4081/reumatismo.2023.1584.ABSTRACTAntiphospholipid syndrome (APS) can affect different organ systems, including the heart and adrenal glands. Despite being known for its prothrombotic characteristics, APS can have serious bleeding complications. Occasionally, thrombotic and bleeding episodes can present simultaneously in an APS patient. Whenever these events co-occur, resuming anticoagulation becomes a topic of debate. As such, we present the case of a 43-year-old male with triple positive antiphospholipid antibodies, indicating APS, who presented with chest pain. Anticoagulants were switched one month before presentation from warfarin to a direct oral anticoagulant, rivaroxaban. Non-ST elevation myocardial infarction, as well as new-onset left-sided adrenal hemorrhage, were diagnosed. The patient developed adrenal insufficiency; therefore, corticosteroids were administered, and warfarin was resumed to prevent further thrombotic episodes.PMID:37721347 | DOI:10.4081/reumatismo.2023.1584

Source: Reumatismo - September 18, 2023 Category: Rheumatology Authors: G El Hasbani M Del Pilar Morel B Tandoh J F Vargas R Crusio Source Type: research